<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064438</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-D1</org_study_id>
    <nct_id>NCT03064438</nct_id>
  </id_info>
  <brief_title>Efficacy of ACU-D1 in the Treatment of Acne Rosacea</brief_title>
  <official_title>Efficacy of ACU-D1 in the Treatment of Acne Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accuitis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accuitis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the safety, efficacy and tolerability of ACCU-D1 when applied twice daily
      for 12 weeks in adult patients with moderate to severe acne rosacea. Two thirds of
      participants will receive ACCU-D1 while one third will receive vehicle control.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Inflammatory Lesion Count</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy as measure by total inflammatory lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Global Assessment (IGA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy as measured by Investigator Global Assessment (IGA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CEA Score</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>Efficacy as measured by change in CEA score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Lesion Count</measure>
    <time_frame>Week 2, 4, 8, 12, and 14</time_frame>
    <description>Efficacy as measured by change from baseline in total lesion count (papules, pustules and nodules).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEA Score</measure>
    <time_frame>Week 2,4,8, 12 and 14</time_frame>
    <description>Efficacy as measured by change from baseline in CEA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis</measure>
    <time_frame>Week 12</time_frame>
    <description>Efficacy as measure by percentage of patients achieving at least a 50% reduction from baseline inflammatory lesion count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Inflammatory Lesion Count</measure>
    <time_frame>From Baseline to Week 12</time_frame>
    <description>Efficacy as measure by percent change in total inflammatory lesion count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acne Rosacea</condition>
  <arm_group>
    <arm_group_label>ACCU-D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACCU-D1 applied to the face twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle applied to the face twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACCU-D1</intervention_name>
    <description>ACCU-D1</description>
    <arm_group_label>ACCU-D1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Vehicle Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or non-pregnant female at least 18 years of age

          -  Patient has ten to forty inflammatory lesions of rosacea on the face at Randomization

          -  Clinical diagnosis of mild to severe facial rosacea as determined by Investigator's
             Global Assessment (IGA) at Randomization

          -  A score of greater than moderate on the Clinical Erythema Assessment Scale

          -  Informed consent obtained from subject and a copy of the signed consent provided to
             subject

        Exclusion Criteria:

          -  Patient is pregnant or planning to become pregnant

          -  Patient is taking a topical or oral therapy which may affect the patient's rosacea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

